Medulloblastoma - group 3 tumours are malignant tumours of the central nervous system, and one of the most common paediatric tumours. They typically arise from the vermis of the cerebellum and are present in childhood and infancy. They have the worst prognosis of all medulloblastoma groups.
On this page:
Terminology
The nomenclature and classification of medulloblastomas are rapidly evolving. In the 5th edition (2021) of the WHO classification of CNS tumours, group 3 and group 4 medulloblastomas are grouped together under non-WNT/non-SHH tumours, which is in turn divided into 8 subgroups 5.
Epidemiology
Group 3 tumours account for approximately 27% of all medulloblastomas, and have a predilection for males, with a 2:1 male to female ratio 1,4.
They are most frequently encountered in children (4-16 years of age) and infants but are rarely seen in adults 1,2,4.
Pathology
The majority of group 3 medulloblastomas have classic or large cell/anaplastic histology 2. They are associated with MYC amplification 2,4.
Radiographic features
The radiographic features of group 3 tumours are similar to group 4 tumours (which we typically associate with medulloblastomas; midline masses arising from the vermis). Unlike group 4 tumours, group 3 tumours tend to be less well defined but have more prominent enhancement 3.
For more details on radiographic features, please refer to the general article on medulloblastomas.
Treatment and prognosis
Surgery is the first line of therapy (as is the case in all medulloblastomas) with the aim being histological proof, molecular subtyping and maximal tumour resection, with adjuvant therapy depending on an overall risk profile (see general article on medulloblastoma) 2.
The incidence of CNS metastatic disease in group 3 tumours at diagnosis is common, found in 30% of all cases, and is even more frequent in infants (47%) 1,2. This often is the case even when the tumour is small, which can be a clue to the diagnosis pre-operatively 4.
Group 3 tumours have the worse prognosis compared to other subtypes of medulloblastoma, similar to group 4 tumours, but significantly worse than SHH and WNT subtypes 1,2:
- 39% 10-year overall survival in infants
- 50% 10-year overall survival in children
Prognosis is also influenced by histological subtype.
Unable to process the form. Check for errors and try again.